Profitability This table compares Arch Therapeutics and SANUWAVE Health's net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Arch Therapeutics -8,257.70%
Sanuwave Health Reports Preliminary Q4 2025 Revenue of $13.3–$13.4 Million, Up 29–30% Year-over-Year; Achieves Record Quarterly and Full-Year Revenue
InfuSystem (NYSE: INFU - Get Free Report) and SANUWAVE Health (OTCMKTS:SNWV - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two compan
Valuation and Earnings This table compares SANUWAVE Health and Carmell"s revenue, earnings per share (EPS) and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings R
AWM Investment Company Inc. reduced its position in Sanuwave Health Inc. (NASDAQ: SNWV) by 4.6% in the second quarter, according to the company in its most recent filing with the Securities and Exchan
EDEN PRAIRIE, Minn. , Dec. 10, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ: SNWV), a leading provider of FDA-approved next-generation wound care products, is p
Healogics Wound Care Supply adds UltraMIST to its Group Purchasing Organization Healogics iSupply and Sanuwave collaborate to provide UltraMIST as an option for GPO members EDEN PRAIRIE, Minn., Dec. 0
Profitability This table compares SANUWAVE Health and Acutus Medical's net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets SANUWAVE Health -1.33% -23.83%
SANUWAVE Health, Inc. ( SNWV ) Q3 2025 Earnings Call November 7, 2025 8:30 AM EST Company Participants Morgan Frank - CEO & Chairman Peter Sorensen - CFO & Secretary Conference Call Participants Ian C
Sanuwave Health Inc. (SNWV) came out with quarterly earnings of $0.46 per share, beating the Zacks Consensus Estimate of $0.32 per share. This compares to a loss of $6.49 per share a year ago.

Sanuwave Announces Q3 FY2025 Financial Results

06:00am, Friday, 07'th Nov 2025
Q3 2025 revenues were  $11.5 million , up 22% from $9.4 million in Q3 2024. This represents the highest quarterly revenues in Company history.
EDEN PRAIRIE, Minn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, wil
Sanuwave Health (SNWV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Institutional and Insider Ownership 42.5% of SANUWAVE Health shares are held by institutional investors. 14.9% of SANUWAVE Health shares are held by insiders. Comparatively, 5.2% of H-CYTE shares are
U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 0.1% on Tuesday.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE